Trial Number

868-18

Age range

45 years and older

Gender

Male or Female

Enrolling Patients

Yes

Full Protocol Title: "AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke [ARCADIA]"

ARCADIA is a multicenter, biomarker-driven, randomized, double-blind, active-control, phase 3 clinical trial of apixaban versus aspirin in patients who have evidence of atrial cardiopathy and a recent stroke of unknown cause. Eleven hundred subjects will be recruited over 2.5 years at 120 sites in the NINDS StrokeNet consortium. Subjects will be followed for a minimum of 1.5 years and a maximum of 4 years for the primary efficacy outcome of recurrent stroke and the primary safety outcomes of symptomatic intracranial hemorrhage and major hemorrhage other than intracranial hemorrhage.

Principal Investigator

MemorialCare Research Center Contact Form

For further information about this study or to express your interest in this study, please fill out and submit this form.